wound infection is a major concern due to the resistance of to topical antibiotics and capacity to inhibit neutrophil migration at the infection site. To overcome these problems, we have developed 0.01% (v/v) octenidine dihydrochloride (Oct) and 0.5% (w/w) chitosan-treated serum (CTS) containing 1.5% (w/v) κ-carrageenan hydrogel (κC). Oct is an antiseptic agent, against which no resistance is reported so far, and CTS has neutrophilic attractant properties. The prepared Oct-CTS-κC hydrogel is injectable and biocompatible. Using in vitro experiments, we demonstrated CTS can induce the migration of polymorphonuclear neutrophils (PMNs) and fibroblasts that can facilitate tissue regeneration at a wound site. In vitro release studies revealed a sustained release of Oct and serum proteins from the Oct-CTS-κC hydrogel. Antibacterial properties of developed hydrogels were tested against and its clinical isolates. Further, the in vivo antibacterial efficacy of the prepared hydrogel was evaluated in an -infected Sprague-Dawley (SD) rat wound. Both in vitro and in vivo studies showed that the Oct-CTS-κC hydrogel inhibited growth. Thus, the developed Oct-CTS-κC hydrogel can be potentially exploited for -infected wound healing.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsabm.8b00625 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!